Dashboard
Boehringer Ingelheim leads the named-sponsor completion-timing gap stock, NCI remains a major public-sector outlier, and NETWORK is the harshest sponsor class on rate.
Boehringer stock
930
Timing-gap studies
NCI stock
601
Timing-gap studies
GOG rate
83.1%
Large-sponsor rate
NETWORK rate
19.2%
Sponsor-class rate
Top sponsor completion-timing stock
Boehringer Ingelheim, NCI, Novartis Pharmaceuticals, and EORTC lead the timing-gap stock table.
The timing-gap table is narrower than the full actual-discipline audit and easier to interpret against deadline logic.
Completion-timing rate
Gynecologic Oncology Group, EORTC, and Eastern Cooperative Oncology Group are the sharpest rate outliers.
Rate again tells a different story from stock.
Missing actual completion dates
The completion-actual component accounts for almost all large sponsor timing gaps in this slice.
That is why Boehringer, NCI, and EORTC stay high whichever timing component is read first.
Sponsor-class timing-gap rate
NETWORK and NIH are much harsher than INDUSTRY or OTHER on completion-timing rate.
This component therefore has a different sponsor-class signature from description black-box opacity.